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The severe acute respiratory syndrome–associated
coronavirus (SARS-CoV) is thought to be transmitted pri-
marily through dispersal of droplets, but little is known
about the load of SARS-CoV in oral droplets. We examined
oral specimens, including throat wash and saliva, and
found large amounts of SARS-CoV RNA in both throat
wash (9.58 x 102 to 5.93 x 106 copies/mL) and saliva (7.08
x 103 to 6.38 x 108 copies/mL) from all specimens of 17
consecutive probable SARS case-patients, supporting the
possibility of transmission through oral droplets.
Immunofluorescence study showed replication of SARS-
CoV in the cells derived from throat wash, demonstrating
the possibility of developing a convenient antigen detection
assay. This finding, with the high detection rate a median of
4 days after disease onset and before the development of
lung lesions in four patients, suggests that throat wash and
saliva should be included in sample collection guidelines
for SARS diagnosis.
S
evere acute respiratory syndrome (SARS) is an emerg-
ing infectious disease that spread rapidly from China to
>30 countries, including Canada, Singapore, Vietnam, and
Taiwan, in the first half of 2003 (1–5). In the latest update
from the World Health Organization, the number of prob-
able SARS cases is 8,096 (5). The etiologic agent of SARS
has been identified as the novel SARS-associated coron-
avirus (SARS-CoV) (6–9). The disease is highly conta-
gious and has the potential to cause a very large epidemic
in the absence of control measures (10–11). Transmission
appears to occur primarily through dispersal of droplets
from the respiratory tract (12), generated when the patient
talks, coughs, or sneezes (4,5,10–13). Although large
amounts of SARS-CoV have been reported in sputum and
nasal specimens, which may account for transmission dur-
ing coughing and sneezing (7,14), little is known about the
load of SARS-CoV in the oral cavity and how the virus is
transmitted during talking. Since sneezing and rhinorrhea
are not common symptoms of SARS, and cough with spu-
tum is only seen in the later stage of infection (1–3,13),
oral droplets generated during talking may represent an
important route of transmission. 
We examined specimens derived from the oropharynx
and oral cavity, including throat wash and saliva, from 17
patients with probable SARS (15,16). Using a quantitative
real-time reverse transcription–polymerase chain reaction
(RT-PCR) assay and fractionation experiment, we investi-
gated the load of SARS-CoV in these samples and differ-
ent components of the throat wash. 
Materials and Methods
Patients
From April 16, 2003, through May 1, 2003, during a 2-
week period of the SARS outbreak in Taipei (16), 17 adult
patients, who were admitted to the emergency department
of the National Taiwan University Hospital and met the
clinical case definitions for probable SARS (15), were
included in this study. Physicians in the SARS Research
Group of National Taiwan University Hospital made the
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Taiwandiagnosis for each patient after thorough evaluation of
their travel or contact history; symptoms; laboratory data
including lymphopenia, thrombocytopenia, and elevated
levels of lactate dehydrogenase or creatine kinase; and
pneumonic patch in the chest x-ray. The first day of fever
was defined as day 1 of illness. The serologic test of an
indirect immunofluorescence assay performed on serum
specimens collected 28 days after onset confirmed SARS-
CoV infection in 13 of the 17 patients. The other four
patients had at least two positive real-time RT-PCR results.
Therefore, all 17 cases with probable SARS in this study
were confirmed by laboratory tests (15).
Sample Processing
With the patient’s consent, saliva and throat wash (by
gargling 10 mL normal saline) were collected in an air-
borne isolation room, according to the guidelines for
aerosol-generating procedures (17). All samples were
transferred to the biosafety level 3 (BSL3) laboratory and
stored at –80°C until use (18). After thawing, 5 mL of the
throat wash was centrifuged at 1,500 x g for 15 min to sep-
arate the supernatant from the mucous-cell pellet. Four
milliliters of the supernatant were collected as the throat
wash supernatant. The remaining 1-mL portion that con-
tained the mucous-cell pellet was treated with equal vol-
ume of N-acetyl-L-cysteine at room temperature for 25
min and centrifuged at 1,500 x g for 15 min to further sep-
arate the cell pellet from the supernatant, of which 1.12 mL
was collected as the treated supernatant of throat wash.
Instead of extensively washing the potentially contagious
cell pellet, we kept the remaining 0.88 mL as the cellular
fraction of throat wash. Equal amounts of the supernatant,
treated supernatant, and cellular fractions were subjected
to viral RNA extraction. An aliquot of the saliva, to which
an equal volume of 1 x phosphate-buffered saline (PBS)
was added, was also subjected to viral RNA extraction.
Isolation of Viral RNA
Viral RNAwas isolated from aliquots of saliva and dif-
ferent fractions of throat wash from the 17 probable SARS
patients and 12 healthy controls by using the QIAamp viral
RNAmini kit (Qiagen, Hilden, Germany) in the BSL3 lab-
oratory (18). Viral RNA was also isolated from culture
supernatants of the SARS-CoV isolate, TW1 (19), human
coronavirus 229E strain, and human enteric coronavirus
Dallas 1 strain (American Type Culture Collection,
Manassas, VA).
Quantitative Real-Time RT-PCR
The assay used forward and reverse primers and a flu-
orogenic probe of the SAR1S_AS Taqman assay design
(Applied Biosystems, Foster City, CA). They matched to a
region within a previously described region of the ORF1b
(6,7), which is also completely conserved by different iso-
lates of SARS-CoV (Figure 1A) (20,21). The sequences of
the forward primer, reverse primers, and probe are 5′-
CACACCGTTTCTACAGGTTAGCT-3′ (genome posi-
tions 15316 to 15338 of the Urbani strain) (20),
5′-GCCACACATGACCATCTCACTTAAT-3′ (positions
15380 to 15356) and 5′-ACGGTTGCGCACACTCGGT-3′
(positions 15355 to 15339), respectively. A200-bp product
covering this region was generated by using the primers
(F1 and R1), the Superscript II one-step RT-PCR system
(Invitrogen, San Diego, CA), and the RNA template
derived from the SARS-CoV TW1 strain (19). The
sequences of the primers F1 and R1 are 5′-CAGAGCCAT-
GCCTAACATGC-3′ (genome positions 15239 to 15258)
(20) and 5′-GCATAAGCAGTTGTAGCATC-3′ (positions
15439 to 15420), respectively. RT-PCR conditions were
52°C for 40 min and 94°C for 2 min, followed by 35 cycles
of 94°C for 1 min, 60°C for 1 min, and 68°C for 45 s. The
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Figure 1. Quantification of the severe acute respiratory syndrome-
associated coronavirus (SARS-CoV) RNA by real-time reverse
transcription–polymerase chain reaction (RT-PCR) assay. (A)
Location of the forward and reverse primers and probe in the
genome of SARS-CoV, with the genome positions shown accord-
ing to the Urbani strain (20). (B) A schematic diagram of the con-
struct, ORF1b/pCRII-TOPO, and the protocol for generating the in
vitro transcribed RNA as the standard for the real-time RT-PCR
assay is shown. The relationship between known input RNA
copies to the threshold cycle (CT) is shown at the bottom.product was subsequently cloned into the TA cloning vec-
tor (Invitrogen, San Diego, CA) to generate the construct,
ORF1b/pCRII-TOPO (Figure 1B). The in vitro transcribed
RNA was purified and quantified to determine the copy
number of RNA as described previously (22). An aliquot
(5  µL) of RNA isolated from the clinical sample and
known amounts of the in vitro transcribed RNA (5 to 50
million copies) were subjected to real-time RT-PCR by
using the SAR1S_AS primers, probe, and the Taqman one-
step real-time RT-PCR master mix reagent kit (Applied
Biosystems). The amplification conditions were 48°C for
30 min and 95°C for 10 min, followed by 45 cycles of
95°C for 15 s and 60°C for 1 min. The ABI prism 7000
sequence detector was used to analyze the emitted fluores-
cence during amplification. A positive result is defined by
the cycle number (CT value) required to reach the thresh-
old as described previously (22). Precautions for PCR
were followed to avoid contamination (23). Since 5 µLo f
50 µL RNA eluates that were derived from 560 µL throat
wash supernatant, was used in each reaction, the number of
SARS-CoV RNA copies per reaction was divided by 56
µL (560 µLx  5  µL/50 µL) and multiplied by 1,000 to
determine the RNA copies per milliliter. The sensitivity of
the assay is 5 copies RNA per reaction, corresponding to
90 copies per milliliter throat wash. 
SARS-CoV RNA in Components of Throat Wash
We used the following formula to calculate the copy
numbers of SARS-CoV RNA in different components
including the supernatant (S), the mucus-associated (M),
and the cell-associated (C) components in the 5-mL throat
wash, which was the starting volume in our fractionation
experiment. The numbers of RNA copies in the S compo-
nent equal the amount (copies/mL) in the supernatant
times 5 (mL) (S = supernatant x 5 mL). Since treatment of
the mucus-cell pellet with N-acetyl-L-cysteine presumably
released SARS-CoV from the mucus and increased the
volume twofold (from 1 mLto 2 mL), the copy numbers in
the M component equal the amount in the treated super-
natant (copies/mL) times 2 mL minus that from the origi-
nally untreated supernatant (1 mL) (M = treated super-
natant x 2 mL– supernatant x 1 mL). The copy numbers in
the C component equal the amount in the cellular fraction
(copies/mL) times the volume of the cell pellet (C = cellu-
lar fraction x volume of cell pellet [in mL]). Taking patient
ID17 as an example, S = 4,790 copies (958 x 5), M = 8,402
copies (4,680 x 2 – 958 x 1), and C = 330 copies (8,460 x
0.039). The amount of SARS-CoV RNA in the cell-free
component, which equals the amount in the S component
plus that in the M component, is 13,192 copies, correspon-
ding to 97.5% of the total SARS-CoV RNAin 5 mL throat
wash, and that in the cell-associated component is 330
copies, corresponding to 2.5% of the total (Table 1). 
Immunofluorescence Assay
Aliquots of the cellular fraction of throat wash from
patients and six healthy controls were fixed onto 12-well
Teflon-coated slides and subjected to a previously
described immunofluorescence assay (19). The first anti-
body was serum from a rabbit immunized with the recom-
binant nucleocapsid protein of the SARS-CoV (prepared
by P.J. Chen), and the secondary antibody was the FITC-
conjugated goat anti-rabbit immunoglobulin G (Pierce
Biotechnology, Rockford, IL). 
Statistical Analysis
Regression analysis was performed to examine the cor-
relation between the sampling day and the amount of
SARS-CoV RNA in throat wash or saliva and the correla-
tion between the amount in throat wash and saliva (soft-
ware SPSS base 10.0, SPSS Inc., Chicago, IL). 
Results
The demographic and clinical information of the 17
patients are summarized in Table 2. Viral RNA was
extracted from saliva and supernatant of the throat wash
and then subjected to a quantitative real-time RT-PCR
assay by using the primers and probe within a highly con-
served region of the ORF1b (Figure 1A) (20,21). Known
amounts of the in vitro transcribed RNA covering this
region were used as the standard for quantification. As
shown in Figure 1B, a linear curve was observed as the
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Table 1. Severe acute respiratory syndrome–associated 
coronavirus (SARS-CoV) RNA in cell-free and cell-associated 
components of throat wash from probable SARS cases 
Copies/5 mL throat wash (% of total) 
Patient 
ID






1  d2  848,000 (99.6)  2,982 (0.4) 
2  d3  34,320 (99.7)  85 (0.3) 
3  d3  10,680 (99.7)  34 (0.3) 
4  d3  119,500 (98.8)  1,495 (1.2) 
5  d3  18,160 (99.6)  72 (0.4) 
6  d4  14,400 (95.4)  695 (4.6) 
7  d4  631,280 (99.9)  416 (0.1) 
8  d4  19,900 (99.4)  124 (0.6) 
9  d4  17,800 (99.5)  91 (0.5) 
10  d5  40,500 (99.9)  60 (0.1) 
11  d5  3,152,000 (99.2)  25,146 (0.8) 
12  d6  1,896,000 (99.4)  12,160 (0.6) 
13  d6  11,100 (99.6)  40 (0.4) 
14  d6  5,992 (99.4)  35 (0.6) 
16  d8  33,400,000 (88.8)  4,222,000 (11.2) 
17  d9  13,192 (97.5)  330 (2.5) 
aPatients of probable SARS were diagnosed according to the World Health 
Organization clinical definitions (15). 
bSampling day 2 (d2) is the second day of fever. 
 input RNA increased from 5 to 50 million copies per reac-
tion. Positive signal was detected in the reactions contain-
ing RNAtemplate derived from the SARS-CoVTaiwanese
strain TW1 but not in those from 12 healthy controls and
from two human coronaviruses (229E strain and human
enteric coronavirus Dallas 1 strain) and not in the reaction
containing no RNA (data not shown) (19,22). 
The results of the real-time RT-PCR assay on the throat
wash and saliva are summarized in Table 2. The sampling
day of these patients varied from day 2 to day 9 after onset
of fever, with a median of day 4. SARS-CoV RNA was
readily detected in throat wash from all 17 patients. The
amount of the SARS-CoV RNA in the throat wash was
9.58 x 102 to 5.93 x 106 copies per mL (median 3.56 x 103
copies/mL). SARS-CoV RNA was also detected in saliva
from all 14 available specimens. The amount of SARS-
CoV RNAin the saliva was 7.08 x 103 to 6.38 x 108 copies
per mL (median 9.92 x 104 copies/mL). The amount of
SARS-CoV RNAin the throat wash or saliva does not cor-
relate with the sampling day (simple linear regression,
coefficient of correlation r = 0.106 and 0.147, respective-
ly), underscoring a more complex course of virus-host
interaction. The amount of SARS-CoV RNA in the saliva
was greater than that in the throat wash for every patient
from whom both type of specimens were available. A lin-
ear relationship existed between the amounts of SARS-
CoV in the saliva and throat wash (simple linear
regression, r = 0.848, p < 0.005), which suggests, but does
not prove, that they could originate from a common source
in the respiratory tract. 
To further investigate whether SARS-CoV is also pres-
ent in the cellular component of the throat wash, we car-
ried out the fractionation experiment and examined the
amount of SARS-CoV RNA in different components. As
shown in Table 1, SARS-CoV RNA was detected in the
cell-associated component of the throat wash from all 16
specimens examined. The range of viral load was
34–4222,000 copies per 5 mL throat wash. While
0.1%–11.2% of SARS-CoV RNA in the throat wash is
present in the cell-associated component, a greater propor-
tion of SARS-CoV RNA, 88.8% to 99.9%, is present in the
cell-free component. This finding suggests that SARS-
CoV is released very efficiently. The possibility that virus
is released from the cells during thawing is unlikely, since
the fractionation experiment performed for aliquots of
some samples without prior freezing and thawing showed
a similar result. For example, in ID7 the percentages of the
cell-associated and cell-free components for an aliquot
performed without freezing were 99.87% and 0.13%,
respectively. These are similar to the results of 99.9% and
0.1% for another aliquot performed after freezing and
thawing (Table 1).
Electron microscopic studies have shown SARS-CoV
particles in the desquamated cells from bronchoalveolar
lavage and lung tissues, both in the lower respiratory tract
(6,8,24). Our detection of SARS-CoV RNA in the cell-
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Table 2. Clinical information and SARS-CoV RNA in throat wash and saliva from probable SARS case-patients
a 
Clinical information at sampling day     
Patient 
ID
b  Age (y)  Sex  Sampling day







1  52  M  d2  Yes  Yes  No
d  Yes  1.58 x 10
5  2.64 x 10
7 
2  28  F  d3  Yes  No  No  Yes  4.69 x 10
3  1.12 x 10
5 
3  47  F  d3  Yes  No  No
d  Yes  1.56 x 10
3  1.06 x 10
5 
4  42  M  d3  Yes  No  No  Yes  2.39 x 10
4  8.22 x 10
4 
5  26  M  d3  Yes  Yes  No  No  3.56 x 10
3  1.22 x 10
4 
6  32  F  d4  Yes  No  No  Yes  2.88 x 10
3  7.08 x 10
3 
7  48  M  d4  Yes  Yes  No  Yes  1.32 x 10
3  9.05 x 10
4 
8  46  M  d4  Yes  No  No  No  3.98 x 10
3  NA 
9  41  F  d4  Yes  No  No
d  No  3.56 x 10
3  NA 
10  47  M  d5  Yes  No  No  Yes  8.10 x 10
3  9.24 x 10
4 
11  52  M  d5  Yes  No  Yes
d  Yes  4.10 x 10
5  1.74 x 10
7 
12  54  M  d6  Yes  Yes  No  Yes  2.46 x 10
5  6.38 x 10
8 
13  48  F  d6  Yes  No  No  Yes  2.22 x 10
3  1.78 x 10
5 
14  26  F  d6  Yes  No  No  Yes  9.73 x 10
2  9.52 x 10
3 
15  21  F  d7  Yes  Yes  No  No  1.74 x 10
3  NA 
16  28  M  d8  Yes  No  No  Yes  5.93 x 10
6  4.14 x 10
7 
17  25  F  d9  Yes  No  Yes  Yes  9.58 x 10
2  2.80 x 10
4 
aSARS-CoV, severe acute respiratory syndrome–associated coronavirus; M, male; F, female; NA = not available. 
bProbable SARS was diagnosed according to the World Health Organization clinical definitions (15). 
cSampling day 2 (d2) is the second day of fever.     
dIntubation for hypoxia was performed during the course of hospitalization.  associated component of the throat wash suggested that
SARS-CoV also replicates in the upper respiratory tract.
To further explore this possibility, we prepared spot slides
from the cellular fraction of the throat wash and examined
them with an indirect immunofluorescence assay by using
a polyclonal serum from a rabbit immunized with a recom-
binant nucleocapsid protein of SARS-CoV. When used in
the epithelial cells prepared from two randomly chosen
specimens (ID11 and ID17), the postimmune serum, but
not the preimmune serum, reacted with epithelial cells
with a speckle pattern (Figure 2, C–D and F–G). The clas-
sification of these cells as epithelial cells was supported by
the size and morphologic features of them under light
microscope (Figure 2H). Only background signal was seen
in the cells prepared from a healthy control (Figure 2E).
These findings indicate that SARS-CoV can replicate in
the epithelial cells of the upper respiratory tract, and such
cells can be used in an antigen detection assay. 
Discussion
We report large amounts of SARS-CoV RNA in the
throat wash and saliva from probable SARS case-patients.
This finding supports the possibility that SARS-CoV can
be transmitted through oral droplets. Most coronaviruses
are known to replicate in the epithelial cells of the respira-
tory or enteric tract. After budding into the pre-Golgi com-
partment, virus particles are released through an
exocytosis-like process at the apical or basolateral surface,
or both (25). Apical release is likely to facilitate the spread
of virus in the respiratory or enteric tract, whereas basolat-
eral release facilitates systemic spread. Our findings that
SARS-CoV can be detected in cells derived from throat
wash by the immunofluorescence assay and that most of
the SARS-CoV in throat wash is present in the cell-free
component suggest that after its replication in the epithe-
lial cells, SARS-CoV is released efficiently and accumu-
lates in the oropharynx and oral cavity, which may
contribute to its transmission through oral droplets. 
Practicing droplet and contact precautions prevents
nosocomial transmission of SARS among healthcare
workers (26). However, a cluster of SARS cases was
reported among apparently protected healthcare workers
during aerosol-generating procedures performed on SARS
patients (27). This finding led to the controversial hypoth-
esis of airborne transmission of SARS, in which very small
particles (<5 µm) are spread in the air (17,27). A substan-
tial proportion, 88.8 % to 99.9%, of the SARS-CoV in the
throat wash was present in cell-free form; this finding
offers a mechanistic explanation of the possibility of air-
borne transmission of SARS. 
Three types of specimens from the upper respiratory
tract, nasopharyngeal aspirates, nasopharyngeal swab, and
oropharyngeal swab have been recommended to detect
SARS-CoV (28,29). However, RT-PCR performed on
nasopharyngeal aspirates from SARS patients had positive
rates of 32% at day 3, 50% at day 5, and 68% at day 14
(8,14). A recent study using nasopharyngeal aspirates
reported a positive rate of 71% at a mean of 4.4 days (30).
In this study, we reported that SARS-CoV RNA can be
detected in both throat wash and saliva from all specimens
examined at an average sampling day 4.8 (range day 2–9).
Furthermore, specimens of throat wash from four of our
study participants who came to our emergency department,
a designated SARS screening site in Taipei during the
SARS outbreak, were collected when radiographic evi-
dence of pneumonia or respiratory distress syndrome had
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Figure 2. Detection of the severe acute respiratory syndrome–associated coronavirus (SARS-CoV) in the epithelial cells in throat wash
from SARS patients by an indirect immunofluorescence assay. (A,B) Spot slides of SARS-CoV–infected Vero E6 cells were incubated
with the preimmune (A) or postimmune (B) serum from a rabbit immunized with the recombinant nucleocapsid protein of the SARS-CoV,
followed by fluorescein isothiocyanate–conjugated goat anti-rabbit immunoglobulin G. Panels A and B demonstrate the specificity of the
reagents. (C to G) Epithelial cells in throat wash from a healthy control (E) and two SARS patients, ID17 (C,D) and ID11 (F,G), were incu-
bated with the preimmune (C,F) or postimmune (D,E,G) rabbit serum. (H) The light microscopic picture of (G), taken with the fluorescent
light on.not been observed (Table 2). To our knowledge, this report
is the first showing that SARS-CoV could be detected in
probable SARS patients before lung lesions developed. 
The high SARS-CoV detection rate in our study con-
trasts with those reported previously by using nasopharyn-
geal aspirates (8,14,30). One possibility is that more
SARS-CoV are present in the oropharynx and oral cavity
than in the nasopharynx. In spite of the differences in the
dilutional factors (for example, 10 mL of normal saline in
the throat wash, 1.5–2 mL in the nasopharyngeal aspirates,
and none in the saliva), the amounts of SARS-CoV RNA
in the throat wash and saliva in our study, 9.58 x 102 to
6.38 x 108 copies per mL, were in the same range as those
previously reported for the nasopharyngeal specimens
(103–108 copies/mL) (7,14). A mutually nonexclusive pos-
sibility is that more respiratory secretions, mucus, and cells
can be removed from the respiratory tract through throat
wash than through nasopharyngeal aspiration, nasopharyn-
geal swabs, and oropharyngeal swabs. Regardless of the
reason, SARS-CoV was also detected in the throat wash of
nine SARS patients in a previous report (6), which sug-
gests the need to evaluate the benefit of collecting throat
wash to diagnose SARS. 
To our knowledge, this report is the first that demon-
strates the possibility of devising a SARS-CoV antigen
detection assay by using cells derived from throat wash.
Since a small number of patients were examined, future
study with more patients and controls is required to devel-
op a useful diagnostic test. Technically, throat wash and
saliva are easier to collect when compared with the collec-
tion of currently recommended respiratory specimens
(28,29). In addition, they can be obtained without close
contact between the patient and healthcare worker, and thus
reduce the risk for infection of healthcare workers. Another
commonly obtained sample is sputum; however, it is rarely
available at the early stage of infection, when virtually no
cough or only dry cough is present (1–3,13). These fea-
tures, together with the high detection rate at early stage
and before the development of lung lesions, suggest that
throat wash and saliva are ideal specimens for early diagno-
sis of SARS and should be included in guidelines for sam-
ple collection for SARS diagnosis (28,29). Further studies
with longitudinally collected throat wash and saliva speci-
mens from a larger number of SARS patients would help
determine the onset and duration of infectiveness, extent of
infectiveness of some patients, such as superspreaders, and
the response to antiviral agents. 
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